share_log

Switzerland To Dispose 10M Expired COVID-19 Vaccine Doses From Moderna

Switzerland To Dispose 10M Expired COVID-19 Vaccine Doses From Moderna

瑞士將處置1000萬劑過期新冠肺炎疫苗
Benzinga Real-time News ·  2022/09/26 06:36
  • Switzerland would have to discard 10.3 million doses of Moderna Inc's (NASDAQ:MRNA) COVID-19 vaccine, the health ministry said Saturday.
  • The ministry said it had no choice but to eliminate the shots after the doses expired.
  • It told the news agency that 2.5 million doses were being stored at a Swiss army logistics base and 7.8 million were in an external storage depot in Belgium.
  • The ministry confirmed an initial report, which estimated that the destroyed doses would be worth around CHF280 million ($285 million).
  • Related: Moderna Provides Vaccine For Preclinical Studies As WHO Tries Developing Its Own COVID-19 Shot.
  • Switzerland ordered doses from various manufacturers to avoid reliance on vaccines that might eventually prove ineffective and to stave off any delivery problems.
  • Vaccines based on mRNA technology from Moderna and Pfizer Inc (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX) turned out to be effective, leaving Switzerland with a surplus of doses.
  • In June, the Swissinfo news site estimated that Switzerland had around 38 million doses of various COVID vaccines that would expire before the year-end.
  • The ministry said that some 3.5 million doses of the new, adapted Moderna vaccine would be available next month.
  • Price Action: MRNA shares closed lower by 0.55% at $123.64 on Friday.
  • 瑞士將不得不丟棄1030萬劑Moderna(納斯達克)衞生部週六表示，新冠肺炎疫苗。
  • 衞生部表示，在疫苗劑量到期後，它別無選擇，只能取消注射。
  • 它告訴通訊社，250萬劑儲存在瑞士軍隊的一個後勤基地，780萬劑儲存在比利時的一個外部儲存庫。
  • 衞生部證實了一份初步報告，該報告估計銷燬的劑量將價值約2.8億瑞士法郎(2.85億美元)。
  • 相關： Moderna為臨牀前研究提供疫苗世衞組織試圖開發自己的新冠肺炎疫苗.
  • 瑞士從不同的製造商那裏訂購了疫苗，以避免對最終可能被證明無效的疫苗的依賴，並避免任何交付問題。
  • Moderna和美國聯合利華的基因工程疫苗輝瑞(紐約證券交易所股票代碼：PFE)和BioNTech SE(納斯達克：BNTX)被證明是有效的，給瑞士留下了過剩的劑量。
  • 今年6月，Swissinfo新聞網站估計，瑞士約有3800萬劑各種COVID疫苗將在年底前到期。
  • 衞生部表示，下個月將有大約350萬劑新的Moderna疫苗供應。
  • 價格行動：上週五，該公司股價收盤下跌0.55%，至123.64美元。
声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論